Targeting IRFs by ubiquitination: regulating antiviral responses. by Higgs, Rowan & Jefferies, Caroline A
Royal College of Surgeons in Ireland
e-publications@RCSI
Molecular and Cellular Therapeutics Articles Department of Molecular and Cellular Therapeutics
1-6-2008
Targeting IRFs by ubiquitination: regulating
antiviral responses.
Rowan Higgs
Royal College of Surgeons in Ireland
Caroline A. Jefferies
Royal College of Surgeons in Ireland
This Article is brought to you for free and open access by the Department
of Molecular and Cellular Therapeutics at e-publications@RCSI. It has
been accepted for inclusion in Molecular and Cellular Therapeutics Articles
by an authorized administrator of e-publications@RCSI. For more
information, please contact epubs@rcsi.ie.
Citation
Higgs R, Jefferies CA. Targeting IRFs by ubiquitination: regulating antiviral responses. Biochemical Society Transactions
2008;36(3):453-8.
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/mctart/27
Ubiquitin and Ubiquitin-Like Modiﬁcation in Health and Disease 453
Targeting IRFs by ubiquitination: regulating
antiviral responses
Rowan Higgs and Caroline A. Jefferies1
Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland
Abstract
The IRF [IFN (interferon) regulatory factor] family of transcription factors control many cellular processes,
including induction of key antiviral cytokines, type I IFNs, following viral infection. Recent studies have
revealed several endogenous and viral proteins involved in ubiquitin-mediated regulation of IRF activity
and thus having an impact on type I IFN signalling. Through the ubiquitin pathway, these proteins can
manipulate the antiviral response either by initiating proteasomal degradation of the IRFs or, in contrast,
by promoting activation of the IRFs.
Introduction
Following viral infection, a crucial step in the antiviral
response is the production of type I IFNs (interferons) [1],
first described in 1957 by Isaacs and Lindemann as proteins
that ‘interfere’ with viral replication [2]. Type I IFNs
include 13–14 IFN-α subtypes, a single IFN-β and other
less characterized family members, such as IFN-ε, IFN-κ
and IFN-ω [3,4]. Secretion of type I IFNs by all nucleated
cells establishes an antiviral state by inducing resistance to
viral replication, increasing MHC class I expression and
antigen presentation, and activating NK (natural killer)
cells to kill virus-infected cells. In addition, IFNs signal
through the IFNAR (type I IFN receptor) to activate ISGF3
(IFN-stimulated factor 3), which induces the transcription
of IFN-inducible genes that contribute to the antiviral state,
including pro-inflammatory cytokines and chemokines
[3,4].
The PRRs (pathogen recognition receptors) responsible
for the innate detection of viruses have been discovered in
recent years and include the TLRs (Toll-like receptors) and
the cytosolic PRRs [RIG-I (retinoic acid-inducible gene I)
and MDA-5 (melanoma-differentiation-associated gene 5)]
[5]. The TLRs recognizing viral nucleic acids (TLR3, TLR7,
TLR8 and TLR9) have evolved in the endosomal compart-
ment of cells, presumably as the endosome is commonly
used for viral entry/exit and viral components collect in
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the endosome following completion of viral replication [6].
Following activation of these TLRs, distinct intracellular
signalling pathways are driven that regulate type I IFN
production. The IRF (IFN regulatory factor) family of
transcription factors are crucial in driving IFN responses
[7]. IRF-3 is involved in the initial induction of IFN-β
downstream of TLR4 and TLR3 and the cytosolic PRR RIG-
I, whereas IRF-5 and IRF-7 are critical for the induction of
TLR7- and TLR9-mediated type I IFN production.
Pathways regulating activation of IRF-3 are well charac-
terized. IRF-3 is expressed ubiquitously and is activated by
serine phosphorylation in response to viral infection or TLR
signalling. Evidence indicates that the kinases TBK1 {TANK
[TRAF (tumour necrosis factor receptor-associated factor)-
associated NF-κB (nuclear factor κB) activator]-binding
kinase 1} and IKKε (inhibitor of NF-κB kinase-ε) specifically
phosphorylate serine residues in the C-terminal domain of
IRF-3 and thereby activate it [8–10]. IRF-7 is similarly
regulated by phosphorylation at C-terminal serine residues,
and IKKε and TBK1 are the kinases responsible [11].
TLR3 is expressed in a wide range of cells and recognizes
dsRNA (double-stranded RNA), although it can also be
activated in vitro with polyI:C, an artificial dsRNA. It
signals through the adaptor molecule TRIF {TIR [Toll/IL
(interleukin)-1 receptor] domain-containing adaptor protein
inducing IFN-β} [12], which interacts with TRAF-3 to
activate both TBK1 and IKKε [13,14]. TLR4, which is
located at the cell surface and recognizes Gram-negative
endotoxin, also induces IFN-β induction through this
TRIF-mediated pathway, although an additional adaptor
molecule, TRAM (TRIF-related adaptor molecule), is
required as a link between TLR4 and TRIF [15,16].
TLR7 and TLR9 signal through the TRIF molecule
MyD88 (myeloid differentiation factor 88), which forms
a complex with TRAF-6 and IRF-7 in the cytoplasm [17].
Formation of this signalling complex has been shown to
be dependent on the serine/threonine kinases IRAK-1
(IL-1-receptor associated kinase-1) and IRAK-4, with
ubiquitination and phosphorylation of TRAF-6 (possibly
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Figure 1 Sequence homology of IRF-3, IRF-5 and IRF-7
(A) General domain structure of the IRF family. SRR, serine-rich region. Certain domains unique to speciﬁc IRFs are not
included. Sequence homology of IRF-1–9 and IRF-3/5/7 are shown below using a colour spectrum with a red colour
indicating high sequence homology. Regions in each colour spectrum represent the homology of the amino acids encoding
the domains directly above in the general IRF structure. (B) Enlargement of the amino acid sequence of IRF-3, IRF-5 and IRF-7
encoding the IAD. All alignments and the subsequent homology colour spectra were produced using T-Coffee, a multiple
sequence alignment program (http://www.bioinformatics.nl/tools/t_coffee.html).
by IRAK-1) being the prerequisite step [18]. Recently,
it has been shown that TLR9-dependent production of
IFN-β in myeloid dendritic cells and macrophages is IRF-
7-independent, and utilizes IRF-1 instead, suggesting that
the immune system can tailor its response to viral pathogens
through the TLR–IRF pathways [18a].
IRFs
The IRF family of transcription factors share an N-terminal
DBD (DNA-binding domain), which binds to the ISRE
(IFN-stimulated regulatory element) in the promoter region
of IFN-stimulated genes. Each IRF, with the exception of
IRF-1 and IRF-2, also contains a unique C-terminal IAD
(IRF association domain), which is important for protein–
protein interaction and thus determines specificity. There
is low sequence homology of the IAD domain across the
IRF family; however, specific IRFs, such as IRF-3, IRF-5
and IRF-7, are more homologous in this region (Figure 1),
possibly due to the importance of these proteins in the
antiviral immune response.
IRFs have been shown to be crucial for specificity in type I
IFN induction, which is discussed in the present review.
However, IRF family members are also known to have roles
in shaping the adaptive immune response, in cell differenti-
ation and in tumour suppression [19–22]. Despite these other
important roles for IRF family members, most of the studies
on these transcription factors have focused on their role in
the regulation of type I IFN induction. In this context, the
functions of IRF-3 and IRF-7 have been shown to be critical.
IRF-3
IRF-3 is a constitutively expressed member of the IRF family
that regulates the primary induction of IFN-β in response to
viral and bacterial infections downstream of TLR3, TLR4 and
cytosolic PRRs. IRF-3 utilizes an autoinhibitory mechanism
to suppress its transactivation potential in uninfected cells.
Following viral infection, phosphorylation of IRF-3 by
C©The Authors Journal compilation C©2008 Biochemical Society
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IKKε and TBK1 occurs on Ser385 and Ser386 and on a
serine/threonine cluster located between amino acids 396 and
405, as determined by the generation of point mutations at
these residues [23,24]. Phosphorylation of IRF-3 disrupts
an interaction between the helices H1 and H5 that flank
the β-sandwich core of the IAD, thus liberating the
DNA-binding activity [25]. Following this, IRF-3 becomes
activated, dimerizes and translocates to the nucleus, where
it associates with the co-activator CBP [CREB (cAMP-
response-element-binding protein)-binding protein]/p300
[23,24]. IRF-3 induces IFN-β transcription by binding to
overlapping regions of PRD III (positive regulatory domain
III) and PRD I on the enhancer region of the IFN-β promoter.
The importance of IRF-3 in the antiviral response has been
confirmed since IRF-3−/− mice are more vulnerable to viral
infection and have lower serum type I IFN levels [26].
Furthermore, cells lacking both IRF-3 and IRF-7 failed to
induce type I IFN mRNA following viral infection, an effect
that could be reversed by co-expression of both proteins [26].
IRF-7
IRF-7 is an inducible member of the IRF family and is vital
for IFN-α production following viral infection, as shown
using IRF-7−/− mice [11]. IRF-7 expression can be induced
directly after viral infection by TLR7 and TLR9 in pDCs
(plasmacytoid dendritic cells), although IFN signalling
through the IFNAR also promotes IRF-7 expression and is
important for the secondary IFN response [27]. In addition
to its inducibility, IRF-7 has a more transient expression
than IRF-3, with a half-life of 30–60 min [26]. The structure
of IRF-7 shares similarities to that of IRF-3 and contains
multiple C-terminal regulatory regions that are the target
of virus-induced phosphorylation by TBK1, and, to a
lesser extent, IKKε [28]. Specifically, Ser477–Ser479 have
been shown to be important for IRF-7 phosphorylation,
whereas Ser471–Ser472 are important for IRF-7 activation
[29]. In addition, it has been shown that IRF-7 is acetylated
in vivo at Lys92 by the histone acetyltransferases P/CAF
(p300/CBP-associated factor) and GCN5 (positive general
control of transcription-5), a post-translational modification
that inhibits its DNA-binding activity [30].
Ubiquitin-mediated regulation of IRFs
Cellular mechanisms that limit or down-regulate type I IFN
production downstream of pathogen recognition are critical
to protection against overproduction of these cytokines,
which can contribute to the adverse pathogenic effects
characteristic of many autoimmune disorders. For example,
SLE (systemic lupus erythematosus) patients present with
high levels of serum type I IFN, which correlates with both
disease severity and pathogenesis [31]. The molecular mech-
anisms that contribute to the overproduction of type I IFNs
in SLE patients is under intense investigation. Studies in
SLE-prone mice have linked both the TLR7- and TLR9-
dependent pathways with this effect, with autoimmune
complexes being shown to activate both TLR7 and TLR9
in driving autoantibody and type I IFN production [32,33].
Intriguingly, polymorphisms in the transcription factor
IRF-5, important in regulating IFN production downstream
of TLR7 and TLR9, have been linked with SLE, although
the functional relevance of these polymorphisms is as
yet unknown. Thus understanding how IRF activity is
both positively and negatively regulated is critical for
understanding how defects in these pathways contribute to
both antiviral defence and autoimmunity.
It has become apparent in recent years that an effective
mechanism to limit type I IFN production is through
ubiquitin-mediated degradation of the IRF family members,
specifically IRF-3 and IRF-7. Ubiquitin-mediated pro-
teasomal degradation is an efficient cellular process that con-
tributes to many biological events including cell cycle control,
signal transduction, DNA repair and apoptosis [34,35]. In
this process, ubiquitin associates with, and is activated by, an
E1 ubiquitin-activating enzyme. It is then transferred via
an E2 ubiquitin-conjugating enzyme to specific lysine
residues of target proteins, an action that is mediated by one
of a large heterogeneous series of E3 ubiquitin ligases. The
E3 ligase is vital and provides the specificity in the ubiquitin
process as it recruits both the E2–ubiquitin complex and
the substrate protein [36]. Addition of further ubiquitin
molecules through lysine–glycine bonding results in the
formation of a polyubiquitin chain that targets the substrate
protein for proteasomal degradation by the 26S protein
complex. The specific lysine targeted by the E3 ligase to
generate polyubiquitin chains on the target protein is critical,
as Lys48-linked ubiquitination generally leads to proteasomal
degradation, whereas Lys63-linked ubiquitination appears to
promote activation of the substrate protein.
Negative ubiquitin-mediated regulation
Ubiquitin-mediated degradation of IRF-3 has been
described in several studies and falls into two main categories
summarized in Figure 2. First, several endogenous proteins
have been described that, after viral infection, directly
or indirectly contribute to the polyubiquitination and
subsequent proteasomal degradation of IRF-3 in order
to protect the host from overproduction of type I IFNs.
Secondly, it has been shown that viral proteins can act as E3
ubiquitin ligases and similarly target IRF-3 for proteasomal
degradation, thus limiting the antiviral response and creating
a more promising cellular environment for viral replication.
The existence of endogenous or viral proteins that target
IRF-3 for degradation was suggested from early work in
which the proteasome inhibitor MG-132 (carbobenzoxy-
L-leucyl-L-leucyl-leucinal) inhibited IRF-3 degradation in
response to viral infection [23]. Recently, IRF-3 activation
was shown to be negatively regulated by the peptide-prolyl
isomerase Pin1. Specifically, Pin1 was shown to interact
with phosphorylated IRF-3 at Ser339 following polyI:C
stimulation of HEK-293T cells [HEK-293 cells (human
embryonic kidney cells) expressing the large T-antigen of
SV40 (simian virus 40)] [37]. This interaction was necessary
C©The Authors Journal compilation C©2008 Biochemical Society
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Figure 2 Ubiquitin-mediated negative regulation of IRF-3 signalling
Viral nucleic acid is recognized by endosomal TLRs and intracellular PRRs (RIG-I and MDA-5). Activation of TLR3 and RIG-I
results in phosphorylation of IRF-3 by IKKε and TBK1. Following this, several endogenous or viral proteins (indicated in
a broken red box) interact with IRF-3 and induce polyubiquitination of the transcription factor. Polyubiquitinated IRF-3 is
targeted for degradation in the 26S proteasome, thus limiting type I IFN production. The endogenous proteins Pin1 and Ro52
are indicated in red, and the viral proteins NSP1, Npro and bICP0 are indicated in red and italics. IRF-7 can be ubiquitinated
by TRAF-6 or RIP (indicated in dashed green box), leading to activation of the transcription factor. Protein phosphorylation is
indicated by an encircled ‘P’.
for the polyubiquitination and proteasomal degradation of
the IRF-3 and the subsequent negative regulation of IFN-
β production [37]. Accordingly, Pin1−/− mice had elevated
serum levels of IFN-β in comparison with wild-type mice
following polyI:C injection [37]. However, Pin1 does not
directly catalyse the ubiquitination of IRF-3. A separate study
into the endogenous mechanisms to down-regulate type I
IFN signalling downstream of pathogen detection demon-
strated the involvement of a cullin-based ubiquitin ligase
in Sendai virus-induced IRF-3 degradation [38], suggesting
that endogenous enzymes may contribute to the negative
regulation of IRF-3. In this context, recent evidence in our
laboratory suggests that the E3 ubiquitin ligase Ro52 [TRIM
(tripartite motif) 21] is directly responsible for ubiquitinating
and targeting IRF-3 for proteasomal degradation. Ro52 is a
member of the TRIM/RBCC [RING (really interesting new
gene) finger B-box coiled-coil] family of single-protein E3
ligases, members of which have been shown to play important
roles in antiviral defence (reviewed in [39,40]). Ubiquitination
and degradation of IRF-3 were substantially increased in
HEK-293T cells co-expressing Ro52, an effect that could be
inhibited with the proteasome inhibitor MG-132 (R. Higgs,
J. Nı´ Gabhann, N. Ben Larbi, E.P. Breen, K.A. Fitzgerald and
C.A. Jefferies, unpublished work). Moreover, knockdown
of Ro52 expression with shRNA (small-hairpin RNA)
resulted in enhanced TLR3-driven IFN-β production and
Sendai virus-stimulated RANTES (regulated upon activation,
normal T-cell expressed and secreted) production (R. Higgs,
J. Nı´ Gabhann, N. Ben Larbi, E.P. Breen, K.A. Fitzgerald and
C.A. Jefferies, unpublished work). In a separate study, Ro52
was shown to ubiquitinate the transcription factor IRF-8,
which positively regulates IL-12p40 production in murine
macrophages [41]; thus Ro52 may have a global role in the
regulation of IRF activity.
Another emerging area of study is the down-regulation of
IRF-3 activation by viral proteins. For example, following
rotaviral infection of Caco-2 cells, the rotavirus gene 5
product, NSP1 (non-structural protein 1), associates with
IRF-3 and mediates degradation of the transcription factor
[42]. In contrast, less IRF-3 degradation was observed in
C©The Authors Journal compilation C©2008 Biochemical Society
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Caco-2 cells infected with a rotaviral strain expressing a
C-terminal truncated version of NSP1, confirming the
immunosuppressive role of this viral protein [42]. Further
work showed that NSP1-mediated IRF-3 degradation is
dependent on the integrity of the N-terminal zinc-binding
domain of NSP1, supporting the hypothesis that NSP1 is
an E3 ubiquitin ligase [43]. The pestiviruses CSFV (classical
swine fever virus) and BVDV (bovine viral diarrhoea virus)
interact with and induce degradation of IRF-3, but not IRF-7,
through the protein Npro [44,45]. In addition, bICP0 [BHV1
(bovine herpesvirus 1)-ICP0 (infected cell protein 0)] has been
shown to act as an E3 ligase and promote IRF-3 degradation
in a proteasome-dependent manner, thus inhibiting the IFN-
β promoter [46]. Accordingly, HSV-1 (herpes simplex virus 1)
ICP0 protein has also been shown to inhibit IRF-3 activity in
a proteasome-dependent manner [47]. Furthermore, a recent
study has shown that the HIV-1 accessory proteins VPR (viral
protein R) and VIF (viral infectivity factor) can modulate the
antiviral response by targeting IRF-3 for degradation [48].
Ubiquitin-mediated degradation of other IRF family
members has also been reported. The C-termini of both
IRF-1 and IRF-8 were shown to be critical for ubiquitination
and proteasomal degradation of these transcription factors
[49,50]. IRF-8 ubiquitination was mediated by the E3 ligase
Cbl and shown to inhibit IL-12p40 production [50], in
contrast with Ro52-mediated ubiquitination of IRF-8, which
appears to regulate functional activity of this transcription
factor [41]. Taken together, these studies demonstrate a
pivotal role for ubiquitin-mediated degradation of IRF
family members, particularly IRF-3, through endogenous or
viral proteins to negatively regulate IFN signalling.
Positive ubiquitin-mediated regulation
Protein degradation is not the only outcome of
ubiquitination, and studies have indicated that IRF activity
can also be enhanced following Lys63-linked ubiquitination
(Figure 2). For example, IRF-7 activity is increased following
Lys63-linked ubiquitination by TRAF-6, which is known to
act as an E3 ubiquitin ligase in TLR signalling [17]. This IRF-
7 ubiquitination occurs in association with the E2 enzyme
UBC13, and reduced IFN-α and IFN-α6 promoter activity
was observed in cells treated with UBC13 siRNA (small
interfering RNA) [17]. In addition, IRF-7 is ubiquitinated
and shows enhanced activity following Epstein–Barr virus
infection [17,51]. Specifically, the viral oncoprotein LMP1
(latent membrane protein 1) stimulates RIP (receptor-
interacting protein)-dependent Lys63-linked ubiquitination
of IRF-7, which leads to an increase in ISRE promoter
activity in luciferase reporter gene assays in HEK-293 cells
[51]. Also, as described above, the TRIM family member
Ro52 acts as an E3 ligase to ubiquitinate the transcription
factor IRF-8, which positively regulates IL-12p40 production
in murine macrophages [41]. Thus activation of IRFs via the
ubiquitin pathway following viral infection appears to be
equally as important as proteasomal degradation.
Conclusion
Following viral infection, ubiquitination of the IRF family of
transcription factors directly regulates type I IFN signalling
by both activating and inhibiting IRF activity. Thus viruses
have evolved mechanisms to manipulate the ubiquitin–
proteasome pathway to aid viral survival. In addition,
proteins such as SUMOs (small ubiquitin-related modifiers)
and DUBs (deubiquitinating enzymes) contribute to the
regulation of this complex system. Further understanding of
the role of ubiquitin in type I IFN pathways may provide
cellular targets for both antiviral treatment and autoimmune
therapy.
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